Incyte (INCY) Stock Could Be 33% Overvalued After Fresh EADV Data

Incyte has delivered a powerful share price run over the past few years, which naturally puts the spotlight on whether that climb is backed by the cash the business can generate. With the stock now trading at US$124.44 at the last close, the key issue is whether the cash flow story lines up with where the market is pricing Incyte today.

• Over the past 3 years, Incyte has returned 112.3%, which raises the question of how much of that gain can be explained by its underlying cash flows.
• Fresh data for Opzelura and other inflammation and autoimmunity treatments, along with expanded access deals such as the Australian ruxolitinib cream partnership and MINJUVI funding in Ontario, may support expectations for future cash generation if these programs convert into durable revenue streams.
• What if you looked at Incyte through its earnings instead? See why Incyte's 15.6x P/E tells a different valuation story.

The issue now is whether Incyte's current share price is adequately supported by the cash flows implied by a Discounted Cash Flow (DCF) intrinsic value estimate.

If you want to test the same cash flow question across a wider field, line up Incyte against 30 high quality undervalued stocks.

Has Incyte Run Too Far on Cash Flow?

The Discounted Cash Flow (DCF) approach here looks at what Incyte’s future cash generation could be worth in today’s dollars. Latest twelve month free cash flow sits around $1.89b, and the 2 Stage Free Cash Flow to Equity model then assumes that this cash stream does not simply climb in a straight line but moves through a phase of softer projections before settling into a more stable level.

Those forward cash flow estimates, which trend lower than the recent $1.89b figure in the outer years, help explain why the DCF output puts Incyte’s estimated intrinsic value substantially below the current share price of $124.44. Because data from Opzelura and other inflammation and autoimmunity treatments is still building out, the market may be placing extra value on optionality from the broader pipeline that the cash flow model does not fully capture. Find out what Incyte could be worth using our Discounted Cash Flow (DCF) estimate.

The Incyte Narrative: What Would Justify Today's Price?

Narratives for Incyte pick up where this valuation puzzle leaves off and explain what kind of future growth, margins and earnings would need to materialise for the stock to be worth materially more or less than today’s price. Each scenario on Simply Wall St’s Community page links a fair value to a clear story about Incyte's potential catalysts and key risks, so you can track which version of events appears to be unfolding over time.

Community views on Incyte are split between those who see more potential in the pipeline and those who focus on post Jakafi cost and execution risk.

Bull case: roughly fairly valued

"Strengthened and diversified product portfolio momentum with Jakafi, Opzelura, Niktimvo, Monjuvi, and Zynyz alongside business development increases resilience against biosimilar threats..."

Discover why this Narrative puts Incyte at roughly fairly valued.

Bear case: 34% overvalued

"Although the Vega deal adds a late stage hematology asset in latarcibart, the roughly US$1.27b upfront payment materially lifts R&D and SG&A..."

Explore why this Narrative puts Incyte at 34% overvalued.

Before focusing on Incyte's valuation alone, check what the risk checks are signalling

Price and cash flows only tell part of the Incyte story, since our broader review has also flagged specific areas of concern that investors may want to inspect in detail. Take a closer look at 2 warning signs (1 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com